Denali Therapeutics Inc.
DNLI
$19.80
$0.341.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 0.08% | -1.30% | -2.24% | 6.66% | -15.87% |
| Total Depreciation and Amortization | -0.56% | -2.07% | -2.38% | 23.16% | 22.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.11% | -3.42% | 1.79% | 6.70% | 13.21% |
| Change in Net Operating Assets | -648.17% | 180.63% | -126.71% | 206.17% | -307.80% |
| Cash from Operations | -33.15% | 8.16% | -42.50% | 42.73% | -57.04% |
| Capital Expenditure | -61.81% | -210.60% | 132.21% | 15.75% | 0.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 334.80% | -60.51% | -65.20% | 580.82% | -86.56% |
| Cash from Investing | 354.83% | -64.09% | -63.38% | 742.41% | -89.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.25% | 98.82% | 44.08% | 44.14% | 47.65% |
| Issuance of Common Stock | -97.93% | 157,785.59% | -85.63% | 581.85% | -85.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 127.46% | -- | -- | -- | -- |
| Cash from Financing | 14.01% | 24,795.76% | -147.94% | 143.14% | 9.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 59.40% | 327.62% | -159.63% | 172.34% | -238.14% |